Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart M Sprague

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Journal of Clinical Medicine|April 12, 2022
Radiomics-Based Image Phenotyping of Kidney Apparent Diffusion Coefficient Maps: Preliminary Feasibility & EfficacyLu-Ping Li, Alexander S Leidner, Emily Wilt, et al.
American Journal of Nephrology|October 5, 2007
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysisEdward A Ross, Jin Tian, Hanna Abboud, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2006
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKDDaniel Coyne, Muralidhar Acharya, Ping Qiu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 8, 2024
Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment DesignationAngelo Karaboyas, Junhui Zhao, Junjie Ma, et al.
American Journal of Nephrology|September 28, 2016
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney DiseaseStuart M Sprague, Paul W Crawford, Joel Z Melnick, et al.
Annals of Surgery|July 18, 2022
The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal HyperparathyroidismSophie Dream, Lindsay E Kuo, Jennifer H Kuo, et al.
Clinical Nephrology|June 8, 2017
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
Daniel W Coyne, Linda H Ficociello, Vidhya Parameswaran, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 19, 2015
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patientsJürgen Floege, Adrian C Covic, Markus Ketteler, et al.
American Journal of Nephrology|January 10, 2015
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney diseaseStuart M Sprague, Arnold L Silva, Fahd Al-Saghir, et al.
Kidney International|December 11, 2002
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismJill S Lindberg, Sharon M Moe, William G Goodman, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Journal of Clinical Medicine|April 12, 2022
Radiomics-Based Image Phenotyping of Kidney Apparent Diffusion Coefficient Maps: Preliminary Feasibility & EfficacyLu-Ping Li, Alexander S Leidner, Emily Wilt, et al.
American Journal of Nephrology|October 5, 2007
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysisEdward A Ross, Jin Tian, Hanna Abboud, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2006
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKDDaniel Coyne, Muralidhar Acharya, Ping Qiu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 8, 2024
Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment DesignationAngelo Karaboyas, Junhui Zhao, Junjie Ma, et al.
American Journal of Nephrology|September 28, 2016
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney DiseaseStuart M Sprague, Paul W Crawford, Joel Z Melnick, et al.
Annals of Surgery|July 18, 2022
The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal HyperparathyroidismSophie Dream, Lindsay E Kuo, Jennifer H Kuo, et al.
Clinical Nephrology|June 8, 2017
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
Daniel W Coyne, Linda H Ficociello, Vidhya Parameswaran, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 19, 2015
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patientsJürgen Floege, Adrian C Covic, Markus Ketteler, et al.
American Journal of Nephrology|January 10, 2015
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney diseaseStuart M Sprague, Arnold L Silva, Fahd Al-Saghir, et al.
Kidney International|December 11, 2002
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismJill S Lindberg, Sharon M Moe, William G Goodman, et al.
Pageof 12